EyePoint advances with Duravyu Phase III trial
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for…
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for…
CAR-Ts are revolutionising the treatment of blood cancers such as B-cell acute lymphocytic leukaemia. However, their success has not yet…
Genentech (San Francisco, CA) has announced an investment exceeding $700m to establish its first East Coast manufacturing facility in Holly…
UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value…
On 20 May at the American Thoracic Society (ATS) 2025 conference in San Francisco, investigators from the Analysis Group, a…
On 20 May 2025 at the American Thoracic Society (ATS) International Conference in San Francisco, a poster presentation by GlaxoSmithKline…
China’s biopharmaceutical sector saw a rise in oncology drug licensing deals in 2024, particularly for monoclonal antibodies (mAbs) and antibody-drug…
At the American Thoracic Society (ATS) 2025 Congress on 19 May, Sanofi and Regeneron announced the launch of a new…
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, researchers from Cincinnati Children’s Hospital presented compelling evidence…
On 19 May, at the 2025 American Thoracic Society (ATS) International Conference, a poster session by researchers from Ghent University…